Industry News
Pharmaceutical Industry News
“FDA will take swift action…
“FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products,” FDA commissioner Marty Makary, M.D., said in a Feb. 5 post on X. The comments mark a
TrumpRx, the President’s Online Drugstore, Opens for Business
TrumpRx is aimed at helping patients use their own money to buy medicines. But researchers who study drug pricing warned that many patients could pay too much if they use the site.
TrumpRx Is Set to Go Live on Thursday
The government website is meant to connect Americans with drug companies to buy prescriptions directly with their own money. It is not clear how many patients will save money.
Amid the fast-moving rollout of…
Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertising’s biggest stage to help get the word out.
On this week’s “The Top Line,”…
On this week’s "The Top Line," Fierce’s Andrea Park and Gabrielle Masson dive into the most anticipated drug launches of 2026 and the blockbuster sales potential shaping biopharma’s next wave.
Amgen added to uncertainty…
Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. Roche penned a deal worth up to $1.7 billion for an RNA interference program from SanegeneBio. Daiichi Sankyo
McKesson’s Kirk Kaminsky…
McKesson’s Kirk Kaminsky discusses community oncology, trials and AI in cancer care.
Thursday evening, President Donald…
Thursday evening, President Donald Trump debuted TrumpRx, a government-run website that directs patients toward cash-pay channels where they can purchase certain prescription drugs.
A month after drugmaker Novo…
A month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims & Hers plans to undercut it with a compounded semaglutide pill offered at a lower price.
The majority of Bristol Myers…
The majority of Bristol Myers Squibb's $48.2 billion revenue haul in 2025 came from its collection of newer growth products as its legacy portfolio declines.
Astellas surpassed market…
Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales.
In its initial public offering,…
In its initial public offering, Veradermics sold a little over 15 million shares of common stock at $17 apiece, raising a total of $256.3 million in its entry onto the New York Stock Exchange, according
Merz Therapeutics has launched a…
Merz Therapeutics has launched a punchy marketing campaign for Parkinson’s disease drug Inbrija, working Muhammad Ali quotes and footage into a revised version of the med’s “For the Fighters” initiative.
F.T.C. Settles With Express Scripts Over High Insulin Prices
The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices.
Novo Nordisk Warns of First Sales Drop Since Start of Ozempic
The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, which gave a much rosier outlook to investors.
By signing a government funding…
By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.
For Sun Pharma, every day—from…
For Sun Pharma, every day—from Super Bowl Sunday and beyond—is “SUNday.”
Eli Lilly said it will be impacted…
Eli Lilly said it will be impacted by pricing pressures in 2026 for its juggernaut products Mounjaro and Zepbound. But the company's momentum is such that it still expects revenues to reach between $80 billion
AbbVie’s immunology drug portfolio…
AbbVie's immunology drug portfolio of Skyrizi, Rinvoq and older Humira contributed $30.4 billion to the company's yearly haul of $61.1 billion.
Novartis CEO Vas Narasimhan is…
Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter results start to show the impact of the “largest patent expiry” in its history.